Table 1.

Ongoing studies on glycolysis and metabolite transporter inhibitors

Target	Drug name	Indication	Highest development stage	Status
Glycolysis inhibitors
Lactate dehydrogenase inhibitor	Nedosiran (DCR PHXC)	Primary hyperoxaluria	Phase III — NCT04042402	Active
Glyceraldehyde 3 phosphate dehydrogenase inhibitor	GP-2250	Pancreatic cancer	Phase II — NCT03854110	Active
	PS101 (3-bromopyruvate)	Solid tumor	Phase I — NCT04021277	Active
Hexokinase 2 inhibitor	Tuvatexib (VDA-1102)	Actinic keratosis	Phase II — NCT03538951	Active
Various targets	2-DG, lonidamine etc			Inactive/discontinued
Transporter inhibitors
CAIX inhibitor	SLC-0111	Pancreatic cancer	Phase II — NCT03450018	Active
CD36 activator	Cyclopsaptide (VT-1021)	Solid tumor	Phase I — NCT03364400	Active
SLC7A5/LAT1 inhibitor	JPH-203	Bile duct cancer	Phase II — UMIN000034080	Active
Various targets	AZD3965, indisulam, MEDI7247			Inactive/discontinued